Cargando…

IVIg attenuates complement and improves spinal cord injury outcomes in mice

OBJECTIVE: Traumatic spinal cord injury (SCI) elicits immediate neural cell death, axonal damage, and disruption of the blood–spinal cord barrier, allowing circulating immune cells and blood proteins into the spinal parenchyma. The inflammatory response to SCI involves robust complement system activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brennan, Faith H., Kurniawan, Nyoman D., Vukovic, Jana, Bartlett, Perry F., Käsermann, Fabian, Arumugam, Thiruma V., Basta, Milan, Ruitenberg, Marc J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931715/ https://www.ncbi.nlm.nih.gov/pubmed/27386499 http://dx.doi.org/10.1002/acn3.318

Ejemplares similares

Targeting acute inflammation to complement spinal cord repair
por: Brennan, Faith H., et al.
Publicado: (2015)

Intravenous immunoglobulin (IVIg) dampens neuronal toll-like receptor-mediated responses in ischemia
por: Lok, Ker Zhing, et al.
Publicado: (2015)

Intravenous immunoglobulin (IVIg) provides protection against endothelial cell dysfunction and death in ischemic stroke
por: Widiapradja, Alexander, et al.
Publicado: (2014)

Analysis and Functional Consequences of Increased Fab-Sialylation of Intravenous Immunoglobulin (IVIG) after Lectin Fractionation
por: Käsermann, Fabian, et al.
Publicado: (2012)

IVIG regulates the survival of human but not mouse neutrophils
por: Schneider, Christoph, et al.
Publicado: (2017)

Mechanism of increased efficacy of recombinant Fc‐μTP‐L309C compared to IVIg to ameliorate mouse immune thrombocytopenia
por: Lewis, Bonnie J.B., et al.
Publicado: (2021)

Complement activation in the injured central nervous system: another dual-edged sword?
por: Brennan, Faith H, et al.
Publicado: (2012)

Traumatic Spinal Cord Injury and the Gut Microbiota: Current Insights and Future Challenges
por: Jogia, Trisha, et al.
Publicado: (2020)

Comparison between 2D and 3D MEDIC for human cervical spinal cord MRI at 3T
por: Asiri, Abdullah, et al.
Publicado: (2020)

Different IVIG Glycoforms Affect In Vitro Inhibition of Anti-Ganglioside Antibody-Mediated Complement Deposition
por: Sudo, Makoto, et al.
Publicado: (2014)

Treatment of scleromyxedema with IVIg
por: Moser, David W, et al.
Publicado: (2012)

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

Dimeric IgG complexes from IVIg are incapable of inducing in vitro neutrophil degranulation or complement activation
por: Kustiawan, Iwan, et al.
Publicado: (2018)

Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer
por: Lewis, Bonnie J. B., et al.
Publicado: (2019)

A Comparative Study of IVIG versus IVIG with IV Methylprednisolone in Guillain–Barre Syndrome
por: Bhattiprolu, Rahi Kiran, et al.
Publicado: (2020)

Human immune cells infiltrate the spinal cord and impair recovery after spinal cord injury in humanized mice
por: Carpenter, Randall S., et al.
Publicado: (2019)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Complement receptor 2 is up regulated in the spinal cord following nerve root injury and modulates the spinal cord response
por: Lindblom, Rickard P. F., et al.
Publicado: (2015)

Effect of intravenous immunoglobulin (IVIg) on primate complement-dependent cytotoxicity of genetically engineered pig cells: relevance to clinical xenotransplantation
por: Yamamoto, Takayuki, et al.
Publicado: (2020)

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
por: Zhang, Wei, et al.
Publicado: (2023)

Peripheral white blood cell responses as emerging biomarkers for patient stratification and prognosis in acute spinal cord injury
por: Jogia, Trisha, et al.
Publicado: (2021)

Eczematous reaction to IVIG for the treatment of dermatomyositis()()
por: Berk-Krauss, J., et al.
Publicado: (2018)

Protocol for Short- and Longer-term Spatial Learning and Memory in Mice
por: Willis, Emily F., et al.
Publicado: (2017)

Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
por: Zhu, Xiao-Lu, et al.
Publicado: (2022)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

Unleashing Spinal Cord Repair: The Role of cAMP-Specific PDE Inhibition in Attenuating Neuroinflammation and Boosting Regeneration after Traumatic Spinal Cord Injury
por: Mussen, Femke, et al.
Publicado: (2023)

Lymphocytes Are Not Required for Neurogenic Heterotopic Ossification Development after Spinal Cord Injury
por: Alexander, Kylie A., et al.
Publicado: (2022)

Complement C6 deficiency exacerbates pathophysiology after spinal cord injury
por: Su, Diane, et al.
Publicado: (2020)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

A case report of complement C4B deficiency in a patient with steroid and IVIG-refractory anti-NMDA receptor encephalitis
por: Chua, Gilbert T., et al.
Publicado: (2020)

Acute IL-1RA treatment suppresses the peripheral and central inflammatory response to spinal cord injury
por: Yates, Abi G., et al.
Publicado: (2021)

IVIG Treatment and Prognosis in Guillain–Barré Syndrome
por: van Doorn, Pieter A., et al.
Publicado: (2010)

IVIG Effects on Erythrocyte Sedimentation Rate in Children
por: Salehzadeh, Farhad, et al.
Publicado: (2014)

Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
por: De Groot, Anne S., et al.
Publicado: (2013)

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008)

Unraveling the mechanisms of IVIG immunotherapy in MIS-C
por: Ganigara, Madhusudan, et al.
Publicado: (2021)

Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
por: DeBiasi, Roberta L.
Publicado: (2021)

MIS-C Treatment: Is IVIG Always Necessary?
por: Licciardi, Francesco, et al.
Publicado: (2021)

Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord
por: Ohmi, Yuhsuke, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dra6ma18jpaa32ah84vj0sktj3